We have built a platform that enables drug discovery and development for previously undruggable genome regulators ("the regulome"). We accomplish this by moving drug discovery out of artificial systems where regulome proteins fail to function properly, and back into live human cells. Our technology combines innovations in automated cell processing, next-gen proteomics, and advanced data analytics to measure a drug's effect on the entire regulome in one experiment.
I'm the co-founder of Talus Bio. Prior to Talus, I trained with Jay Bradner at Harvard in medicinal chemistry, drug screening, and drug development for gene regulators. After that, I moved to Seattle to continue my training in epigenomics and proteomics, and these were all combined to develop the Talus gene regulator platform.
I'm Talus Bio's CTO, where my focus is on developing techniques for quantitative proteomics and in particular the challenges associated with scaling-up quantitative proteomics experiments. I’ve trained at the Broad Institute, the University of Washington, and most recently the University of Pennsylvania.